Proportional Upregulation of CD97 Isoforms in Glioblastoma and Glioblastoma-Derived Brain Tumor Initiating Cells

CD97 is a novel glioma antigen that confers an invasive phenotype and poor survival in patients with glioblastoma (GBM), the most aggressive primary malignant brain tumor. The short isoform of CD97, known as EGF(1,2,5), has been shown to promote invasion and metastasis, but its role in gliomas and GBM-derived brain tumor initiating cells (BTICs) has not been studied. We sought to characterize CD97 expression among gliomas and identify the specific isoforms expressed. The short isoform of CD97 was identified in GBM and GBM-derived BTICs, but not low grade or anaplastic astrocytomas. All samples expressing the EGF(1,2,5) isoform were also found to express the EGF(1,2,3,5) isoform. These isoforms are believed to possess similar ligand binding patterns and interact with chondroitin sulfate, a component of the extracellular matrix, and the integrin α5β1. Using data acquired from the Cancer Genome Atlas (TCGA), we show that CD97 is upregulated among the classical and mesenchymal subtypes of GBM and significantly decreased among IDH1 mutant GBMs. Given its proven roles in tumor invasion, expression among aggressive genetic subtypes of GBM, and association with overall survival, CD97 is an attractive therapeutic target for patients with GBM.

[1]  M. Schrappe,et al.  Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. , 1991, Cancer research.

[2]  B. Liu,et al.  Enhanced invasion in vitro and the distribution patterns in vivo of CD133+ glioma stem cells. , 2011, Chinese medical journal.

[3]  Susan Chang,et al.  Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery , 2011, Journal of Neuro-Oncology.

[4]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[5]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[6]  G. Minniti,et al.  Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. , 2012, Anticancer research.

[7]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[8]  Liu Yong,et al.  Role of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. , 2005 .

[9]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[10]  Ugo Orfanelli,et al.  Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.

[11]  Yun-jie Wang,et al.  Human brain glioma stem cells are more invasive than their differentiated progeny cells in vitro , 2012, Journal of Clinical Neuroscience.

[12]  R. V. van Lier,et al.  Characterization of the CD55 (DAF)‐binding site on the seven‐span transmembrane receptor CD97 , 1998, European journal of immunology.

[13]  Anthony Asher,et al.  Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. , 2003, Journal of neurosurgery.

[14]  M. Raffeld,et al.  LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. , 2011, Cancer research.

[15]  David T. W. Jones,et al.  IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. , 2009, Neuro-oncology.

[16]  C. Klein,et al.  Invasive behaviour of human gliomas is mediated by interindividually different integrin patterns. , 1998, Anticancer research.

[17]  John Q. Davies,et al.  The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. , 2003, Blood.

[18]  Chao Li,et al.  The Invasion and Metastasis Promotion Role of CD97 Small Isoform in Gastric Carcinoma , 2012, PloS one.

[19]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[20]  D. Davies,et al.  The role of integrin receptors in aspects of glioma invasion in vitro , 1999, International Journal of Developmental Neuroscience.

[21]  D. Zagzag,et al.  Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins. , 1996, Cancer research.

[22]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[23]  Markus Loeffler,et al.  Tumorigenesis and Neoplastic Progression Individual Cell-Based Models of Tumor-Environment Interactions Multiple Effects of CD 97 on Tumor Invasion , 2006 .

[24]  P. Kleihues,et al.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. , 2009, The American journal of pathology.

[25]  P. Meltzer,et al.  CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model , 2013, Oncogene.

[26]  W. Scherbaum,et al.  CD97: a dedifferentiation marker in human thyroid carcinomas. , 1997, Cancer research.

[27]  W. Vandertop,et al.  The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma , 2010, Acta Neuropathologica.

[28]  Haino,et al.  Structural characterization of mouse CD97 and study of its specific interaction with the murine decay‐accelerating factor (DAF, CD55) , 1999, Immunology.

[29]  Mitchel S Berger,et al.  Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. , 2005, Journal of neurosurgery.

[30]  G. Aust,et al.  Expression characteristics of the human CD97 antigen. , 1997, Tissue antigens.

[31]  Qiulian Wu,et al.  Elevated invasive potential of glioblastoma stem cells. , 2011, Biochemical and biophysical research communications.

[32]  Jeffrey C. Allen,et al.  Migration of Brain Tumor Cells on Extracellular Matrix Proteins in Vitro Correlates with Tumor Type and Grade and Involves αv and β1 Integrins , 1996 .

[33]  ShaoChuang Wang,et al.  Immunohistochemical Expression and Prognostic Value of CD97 and Its Ligand CD55 in Primary Gallbladder Carcinoma , 2012, Journal of biomedicine & biotechnology.

[34]  Christian Mawrin,et al.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.

[35]  G. Aust,et al.  CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. , 2002, American journal of clinical pathology.

[36]  I. Mackenzie,et al.  Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. , 2011, Cancer research.

[37]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[38]  Andrey Korshunov,et al.  Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.

[39]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[40]  G. Parkin,et al.  Long-term tripotent differentiation capacity of human neural stem (NS) cells in adherent culture , 2008, Molecular and Cellular Neuroscience.

[41]  H. Okano,et al.  Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin , 2009, Proceedings of the National Academy of Sciences.

[42]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[43]  Alexander Brawanski,et al.  CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. , 2007, Cancer research.

[44]  Martin Stacey,et al.  Molecular Analysis of the Epidermal Growth Factor-like Short Consensus Repeat Domain-mediated Protein-Protein Interactions , 2001, The Journal of Biological Chemistry.

[45]  W. Broaddus,et al.  Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness. , 2012, Journal of neurosurgery.

[46]  Koji Yoshimoto,et al.  Distinct transcription profiles of primary and secondary glioblastoma subgroups. , 2006, Cancer research.

[47]  D. Buckley,et al.  Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients , 2003, Cancer Immunology, Immunotherapy.

[48]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.

[49]  G. Aust,et al.  Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. , 2002, The American journal of pathology.

[50]  S. Gordon,et al.  Adhesion-GPCRs: emerging roles for novel receptors. , 2008, Trends in biochemical sciences.

[51]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  F. Lang,et al.  Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by β8 integrin. , 2011, Cancer research.

[53]  Karine Tremblay,et al.  High-throughput quantification of splicing isoforms. , 2010, RNA.

[54]  R. Finke,et al.  The expression of CD97EGF and its ligand CD55 on marginal epithelium is related to higher stage and depth of tumor invasion of gastric carcinomas. , 2005, Oncology reports.

[55]  Mark Bernstein,et al.  Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. , 2009, Cell stem cell.

[56]  Q. Duh,et al.  Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. , 1995, European journal of endocrinology.

[57]  Tzong-Shiue Yu,et al.  A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .

[58]  M. Berger,et al.  Overexpression of CD97 Confers an Invasive Phenotype in Glioblastoma Cells and Is Associated with Decreased Survival of Glioblastoma Patients , 2013, PloS one.

[59]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[60]  W. Stetler-Stevenson,et al.  CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. , 2005, Blood.

[61]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[62]  D. Herr,et al.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. , 2010, Prostaglandins & other lipid mediators.